His research group is studying the cellular processes and molecular interplay underlying the functions of the two most abundant proteins in blood, albumin and IgG. Such knowledge offers opportunities for development of novel concepts that will secure improved half-life and biodistribution of IgG and albumin based therapeutics. The laboratory has an eye on translational research, is highly innovative and is the research group at the University of Oslo and Oslo University Hospital with most registered innovations at Inven2. The laboratory is collaborating extensively with biotech and pharmaceutical companies.